StockData
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. (SRPT) stock

SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.77−0.36 (-2.38%)

Close on Nov 17, 2026Market cap $1.56BP/E –Yield –

Sarepta Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Sarepta Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$143.25M. For fiscal 2025 it was -$699.78M, down 420.9% from the year before. The highest annual figure on record is $218.08M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$699.78M-420.9%
FY2024Dec 31, 2024$218.08M–
FY2023Dec 31, 2023-$267.82M–
FY2022Dec 31, 2022-$536.20M–
FY2021Dec 31, 2021-$459.71M–
FY2020Dec 31, 2020-$564.16M–
FY2019Dec 31, 2019-$705.56M–
FY2018Dec 31, 2018-$343.63M–
FY2017Dec 31, 2017-$171.64M–
FY2016Dec 31, 2016-$266.73M–
FY2015Dec 31, 2015-$220.18M–
FY2014Dec 31, 2014-$133.79M–
FY2013Dec 31, 2013-$90.28M–
FY2012Dec 31, 2012-$29.70M–
FY2011Dec 31, 2011-$35.93M–
FY2010Dec 31, 2010-$20.93M–
FY2009Dec 31, 2009-$15.51M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$13.29M-88.5%
Q1 FY2026Mar 31, 2026$358.43M–
Q4 FY2025Dec 31, 2025-$411.58M-354.6%
Q3 FY2025Sep 30, 2025-$103.39M-565.8%
Q2 FY2025Jun 30, 2025$115.58M–
Q1 FY2025Mar 31, 2025-$300.39M-960.6%
Q4 FY2024Dec 31, 2024$161.68M+556.6%
Q3 FY2024Sep 30, 2024$22.20M–
Q2 FY2024Jun 30, 2024-$701.00K–
Q1 FY2024Mar 31, 2024$34.91M–
Q4 FY2023Dec 31, 2023$24.63M–
Q3 FY2023Sep 30, 2023-$20.84M–
Q2 FY2023Jun 30, 2023-$133.52M–
Q1 FY2023Mar 31, 2023-$138.09M–
Q4 FY2022Dec 31, 2022-$106.83M–
Q3 FY2022Sep 30, 2022-$131.36M–
Q2 FY2022Jun 30, 2022-$211.13M–
Q1 FY2022Mar 31, 2022-$86.88M–
Q4 FY2021Dec 31, 2021-$105.81M–
Q3 FY2021Sep 30, 2021-$34.46M–
Q2 FY2021Jun 30, 2021-$167.57M–
Q1 FY2021Mar 31, 2021-$151.87M–
Q4 FY2020Dec 31, 2020-$170.72M–
Q3 FY2020Sep 30, 2020-$137.07M–
Q2 FY2020Jun 30, 2020-$138.35M–
Q1 FY2020Mar 31, 2020-$118.03M–
Q4 FY2019Dec 31, 2019-$230.22M–
Q3 FY2019Sep 30, 2019-$123.59M–
Q2 FY2019Jun 30, 2019-$275.37M–
Q1 FY2019Mar 31, 2019-$76.39M–
Q4 FY2018Dec 31, 2018-$139.36M–
Q3 FY2018Sep 30, 2018-$70.10M–
Q2 FY2018Jun 30, 2018-$103.43M–
Q1 FY2018Mar 31, 2018-$30.74M–
Q4 FY2017Dec 31, 2017-$23.15M–
Q3 FY2017Sep 30, 2017-$45.91M–
Q2 FY2017Jun 30, 2017-$63.34M–
Q1 FY2017Mar 31, 2017-$39.25M–
Q4 FY2016Dec 31, 2016-$88.40M–
Q3 FY2016Sep 30, 2016-$56.53M–

More Sarepta Therapeutics figures

See a number that looks wrong?